header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

MEDIUM TO LONG TERM SURVIVORSHIP OF THE PLASMACUP



Abstract

Introduction: Between 1987 and 1997 we implanted 319 primary hybrid total hip arthroplasties in 289 patients using the ‘Plasmacup’ (B. Braun Ltd, Sheffield) with a conventional metal on polyethylene articulation. We have observed a high revision rate with this implant recently and therefore undertook a clinical review of this cohort.

Patients and Methods: The indications for surgery were osteoarthritis (223), secondary arthritis (83), inflammatory arthritis (10), and others (3). 17 patients have died and 20 have been lost to follow up. Survival analysis was calculated using implant failure defined as revision (including liner exchange), and includes the censored patients outlined above. Assessment of complications in surviving implants was made using AP radiographs of the hip.

Results: The cup survival rate (Kaplan-Meier method) was 91% at 10 years (95%CI ± 4%) and 67% at 13 years (95%CI +/−9%). The stem survival rate was 96% at 10 years (95%CI +/−3%) and 87% at 13 years (95%CI +/−7%). The median wear in cup revisions for osteolysis was 2.4mm (IQR 1.0–3.2mm), and the median wear in surviving cups was 1.3 mm (IQR 0.8 1.9mm), and was an independent predictor of failure (Cox: p=0.001). There have been 57 revisions (35 cup only, 18 cup and stem, 4 stem only). Indications for revision were osteolysis or loosening (34), wear (18), and infection (5). In surviving cups (214), 29 have expansile acetabular osteolysis and 8 have linear osteolysis. In surviving stems (244), 14 have expansile osteolysis and 23 have linear osteolysis.

Conclusions: There is a high late failure rate of the plasma cup using a conventional metal on polyethylene articulation. Patients with this implant/bearing combination should be closely monitored, particularly after 10 years.

Correspondence should be addressed to Mr Peter Howard, Editorial Secretary, BHS, c/o BOA, The Royal College of Surgeons, 35–43 Lincoln’s Inn Fields, London WC2A 3PE, England.